

Edgar Filing: Calumet Specialty Products Partners, L.P. - Form NT 10-Q

Calumet Specialty Products Partners, L.P.
Form NT 10-Q
November 13, 2017

OMB Approval
OMB Number: 3235-0058
Expires: October 31, 2018
Estimated average burden hours per response. 2.50

SEC FILE NUMBER

000-51734
CUSIP

131476103

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One) Form 10-K Form 20-F Form 11-K Form 10-Q
 Form 10-D Form N-SAR Form N-CSR

For Period Ended: September 30, 2017
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-Q
Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION
CALUMET SPECIALTY PRODUCTS PARTNERS, L.P.

(Full Name of Registrant)
N/A
(Former Name if Applicable)
2780 Waterfront Pkwy E. Drive, Suite 200
(Address of Principal Executive Office (Street and Number))
Indianapolis, IN 46214
(City, State and Zip Code)

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable (a) effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Calumet Specialty Products Partners, L.P. (the "Company") has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017 (the "Form 10-Q") by November 9, 2017, the due date for such filing without unreasonable effort or expense. On September 1, 2017, the Company implemented the first phase of its new Enterprise Resource Planning ("ERP") software system. However, unforeseen difficulties with respect to the implementation have resulted in delays in accounting for the results of the third quarter. The Company is working to finalize its results and currently expects to file its Form 10-Q for the quarter ended September 30, 2017 in late November 2017.

The Company's expectation regarding the timing of the filing of its Form 10-Q and the Company's belief with respect to anticipated changes from the results of operation from the corresponding period of the last fiscal year are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, and actual events may differ materially from those contemplated by these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties, including the inability of the Company to complete the work necessary in order to file its Form 10-Q in the time frame that is anticipated. The Company undertakes no obligation to revise or update any forward-looking statements to reflect actual events or circumstances after the date hereof.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

D. West Griffin (317) 328-5660

(Name) (Area Code) (Telephone Number)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or

(2) Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Based on current information and analysis, the Company estimates select preliminary third quarter fiscal 2017 highlights:

Net Sales above \$1 billion

Liquidity (availability plus cash) above \$400 million

The primary factors contributing to the expected increase in net sales in the three months ended September 30, 2017 are performance improvement in the Company's specialty products segment driven by continued tight supply and self-help initiatives that were partially offset by temporary supply chain disruptions and rising feedstock costs caused by Hurricane Harvey. The fuel products segment exhibited strong operational performance after Hurricane Harvey while the oilfield services segment has continued to show continued operational improvements.

CALUMET SPECIALTY PRODUCTS PARTNERS, L.P.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13,
2017 By /s/ D. West Griffin

D. West Griffin

Executive Vice President and Chief Financial Officer of Calumet GP, LLC, general partner
of Calumet Specialty Products Partners, L.P.

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).